Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis

Journal of Controlled Release

Volumn 130, Issue 2, 2008, Pages 161-167

  Martínez Gómez, Julia M ^a   Csaba, Noémi ^b   Fischer, Stefan ^b   Sichelstiel, Anke ^a   Kündig, Thomas M ^a   Gander, Bruno ^b   Johansen, Pål ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

Immune response; Microparticles; Protamine; Transfection; Uptake

Indexed keywords

AMINO ACIDS; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS; CHEMOTHERAPY; CLADDING (COATING); CONTROLLED DRUG DELIVERY; DRUG DELIVERY; DRUG DOSAGE; ELECTROLYTES; IMMUNOLOGY; NUCLEIC ACIDS; SURFACE CHARGE;

BIODEGRADABLE MICROPARTICLES; CELL PENETRATION; COATED PARTICLES; DRUG RELEASES; IMMUNE RESPONSE; IMMUNE RESPONSES; IMMUNOLOGICAL EFFECTS; IN VITRO STUDIES; IN-VIVO; MICROPARTICLES; PHAGOCYTIC CELLS; PLGA MICROPARTICLES; POLY-LACTIDE-CO-GLYCOLIDE; PROTAMINE; SURFACE COATINGS; SURFACE MODIFICATIONS; T-CELL RESPONSES; TRANSFECTION; UPTAKE;

NANOSTRUCTURED MATERIALS;

ARGININE; CATION; POLYGLACTIN; PROTAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIGEN PRESENTATION; ARTICLE; BIODEGRADABILITY; DRUG COATING; DRUG DELIVERY SYSTEM; EMBRYO; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VITRO STUDY; INTERNALIZATION; MICROENCAPSULATION; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODY FORMATION; ANTIGENS; B-LYMPHOCYTES; CELL LINE; DENDRITIC CELLS; DNA; DRUG CARRIERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GREEN FLUORESCENT PROTEINS; HUMANS; LACTIC ACID; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; PARTICLE SIZE; PHAGOCYTOSIS; POLYAMINES; POLYGLYCOLIC ACID; PROTAMINES; RECEPTORS, ANTIGEN, T-CELL; SURFACE PROPERTIES; T-LYMPHOCYTES; TRANSFECTION;

EID: 49749132317     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.06.003     Document Type: Article

References (50)

1. Varde N.K., and Pack D.W. Microspheres for controlled release drug delivery. Expert Opin. Biol. Ther. 4 1 (2004) 35-51
2. Johansen P., Martinez Gomez J.M., and Gander B. Development of synthetic biodegradable microparticulate vaccines: a roller coaster story. Expert Rev. Vaccines 6 4 (2007) 471-474
3. Mundargi R.C., Babu V.R., Rangaswamy V., Patel P., and Aminabhavi T.M. Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives. J. Control. Release 125 3 (2007) 193-209
4. Langer R. New methods of drug delivery. Science 249 4976 (1990) 1527-1533
5. Putney S.D., and Burke P.A. Improving protein therapeutics with sustained-release formulations. Nat. Biotechnol. 16 2 (1998) 153-157
6. Johansen P., Men Y., Merkle H.P., and Gander B. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur. J. Pharm. Biopharm. 50 1 (2000) 129-146
7. Peyre M., Fleck R., Hockley D., Gander B., and Sesardic D. In vivo uptake of an experimental microencapsulated diphtheria vaccine following sub-cutaneous immunisation. Vaccine 22 19 (2004) 2430-2437
8. Ataman-Onal Y., Munier S., Ganee A., Terrat C., Durand P.-Y., Battail N., Martinon F., Le Grand R., Charles M.-H., Delair T., and Verrier B. Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models. J. Control. Release 112 2 (2006) 175-185
9. Johansen P., Moon L., Tamber H., Merkle H.P., Gander B., and Sesardic D. Immunogenicity of single-dose diphtheria vaccines based on PLA/PLGA microspheres in guinea pigs. Vaccine 18 3-4 (1999) 209-215
10. Men Y., Thomasin C., Merkle H.P., Gander B., and Corradin G. A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide. Vaccine 13 7 (1995) 683-689
11. Peter K., Men Y., Pantaleo G., Gander B., and Corradin G. Induction of a cytotoxic T-cell response to HIV-1 proteins with short synthetic peptides and human compatible adjuvants. Vaccine 19 30 (2001) 4121-4129
12. Peyre M., Audran R., Estevez F., Corradin G., Gander B., Sesardic D., and Johansen P. Childhood and malaria vaccines combined in biodegradable microspheres produce immunity with synergistic interactions. J. Control. Release 99 3 (2004) 345-355
13. Espuelas S., Irache J.M.., and Gamazo C. Synthetic particulate antigen delivery systems for vaccination. Inmunología 24 2 (2005) 208-223
14. Fischer S., Uetz-von Allmen E., Waeckerle-Men Y., Groettrup M., Merkle H.P., and Gander B. The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. Biomaterials 28 6 (2007) 994-1004
15. Singh M., Ott G., Kazzaz J., Ugozzoli M., Briones M., Donnelly J., and O'Hagan D.T. Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA. Pharm. Res. 18 10 (2001) 1476-1479
16. Singh M., Kazzaz J., Ugozzoli M., Chesko J., and O'Hagan D.T. Charged polylactide co-glycolide microparticles as antigen delivery systems. Expert Opin. Biol. Ther. 4 4 (2004) 483-491
17. Singh M., Chesko J., Kazzaz J., Ugozzoli M., Kan E., Srivastava I., and O'Hagan D.T. Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not. Pharm. Res. 21 12 (2004) 2148-2152
18. Singh M., Kazzaz J., Chesko J., Soenawan E., Ugozzoli M., Giuliani M., Pizza M., Rappouli R., and O'Hagan D.T. Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. J. Pharm. Sci. 93 2 (2004) 273-282
19. Fischer S., Foerg C., Ellenberger S., Merkle H.P., and Gander B. One-step preparation of polyelectrolyte-coated PLGA microparticles and their functionalization with model ligands. J. Control. Release 111 1-2 (2006) 135
20. Balhorn R. The protamine family of sperm nuclear proteins. Genome Biol. 8 9 (2007) 227
21. Collins E., Birchall J.C., Williams J.L., and Gumbleton M. Nuclear localisation and pDNA condensation in non-viral gene delivery. J. Gene Med. 9 4 (2007) 265-274
22. Brange J., and Langkjaer L. Insulin formulation and delivery. Pharm. Biotechnol. 10 (1997) 343-409
23. Brange J., and Langkjaer L. Chemical stability of insulin. 3. Influence of excipients, formulation, and pH. Acta Pharm. Nord. 4 3 (1992) 149-158
24. Byun Y., Chang L.C., Lee L.M., Han I.S., Singh V.K., and Yang V.C. Low molecular weight protamine: a potent but nontoxic antagonist to heparin/low molecular weight protamine. ASAIO J. 46 4 (2000) 435-439
25. Martinez Gomez J.M., Fischer S., Csaba N., Kundig T.M., Merkle H.P., Gander B., and Johansen P. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles. Pharm. Res. 24 10 (2007) 1927-1935
26. Dunne M., Bibby D.C., Jones J.C., and Cudmore S. Encapsulation of protamine sulphate compacted DNA in polylactide and polylactide-co-glycolide microparticles. J. Control. Release 92 1-2 (2003) 209
27. Csaba N., Fischer S., Gorodyska G., Textor M., and Merkle H.P. Surface modified microparticles as carriers for nucleic acid vaccines and immunopotentiators. Eur. Cell. Mater. 14 3 (2007) 122
28. Freitas S., Walz A., Merkle H.P., and Gander B. Solvent extraction employing a static micromixer: a simple, robust and versatile technology for the microencapsulation of proteins. J. Microencapsul 20 1 (2003) 67-85
29. Murphy K.M., Heimberger A.B., and Loh D.Y. Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science 250 4988 (1990) 1720-1723
30. Barnden M.J., Allison J., Heath W.R., and Carbone F.R. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 76 1 (1998) 34-40
31. Storni T., Kundig T.M., Senti G., and Johansen P. Immunity in response to particulate antigen-delivery systems. Adv. Drug Deliv. Rev. 57 3 (2005) 333-355
32. Ahmad-Nejad P., Hacker H., Rutz M., Bauer S., Vabulas R.M., and Wagner H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 32 7 (2002) 1958-1968
33. Men Y., Audran R., Thomasin C., Eberl G., Demotz S., Merkle H.P., Gander B., and Corradin G. MHC class I- and class II-restricted processing and presentation of microencapsulated antigens. Vaccine 17 9-10 (1999) 1047-1056
34. Wischke C., Borchert H.-H., Zimmermann J., Siebenbrodt I., and Lorenzen D.R. Stable cationic microparticles for enhanced model antigen delivery to dendritic cells. J. Control. Release 114 3 (2006) 359-368
35. Thiele L., Rothen-Rutishauser B., Jilek S., Wunderli-Allenspach H., Merkle H.P., and Walter E. Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages?. J. Control. Release 76 1-2 (2001) 59-71
36. Thiele L., Merkle H.P., and Walter E. Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages. Pharm. Res. 20 2 (2003) 221-228
37. Schwarze S.R., Hruska K.A., and Dowdy S.F. Protein transduction: unrestricted delivery into all cells?. Trends Cell Biol. 10 7 (2000) 290
38. Futaki S., Suzuki T., Ohashi W., Yagami T., Tanaka S., Ueda K., and Sugiura Y. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276 8 (2001) 5836-5840
39. Jarver P., and Langel U. Cell-penetrating peptides-a brief introduction. Biochim. Biophys. Acta, Biomembr. 1758 3 (2006) 260-263
40. Lundberg P., and Langel U. A brief introduction to cell-penetrating peptides. J. Mol. Recognit. 16 5 (2003) 227-233
41. Brooks H., Lebleu B., and Vives E. Tat peptide-mediated cellular delivery: back to basics. Adv. Drug Deliv. Rev. 57 4 (2005) 559
42. Fittipaldi A., and Giacca M. Transcellular protein transduction using the Tat protein of HIV-1. Adv. Drug Deliv. Rev. 57 4 (2005) 597-608
43. Torchilin V.P. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv. Drug Deliv. Rev. 60 4-5 (2008) 548-558
44. Reynolds F., Weissleder R., and Josephson L. Protamine as an efficient membrane-translocating peptide. Bioconjug. Chem. 16 5 (2005) 1240-1245
45. Park Y.J., Chang L.-C., Liang J.F., Moon C., Chung C.-P., and Yang V.C. Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. FASEB J. 19 11 (2005) 1555-1557
46. Lewin M., Carlesso N., Tung C.H., Tang X.W., Cory D., Scadden D.T., and Weissleder R. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 18 4 (2000) 410-414
47. Torchilin V.P., and Levchenko T.S. TAT-liposomes: a novel intracellular drug carrier. Curr. Protein Pept. Sci. 4 2 (2003) 133-140
48. Torchilin V.P., Levchenko T.S., Rammohan R., Volodina N., Papahadjopoulos-Sternberg B., and D'Souza G.G. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc. Natl. Acad. Sci. U. S. A. 100 4 (2003) 1972-1977
49. Gupta B., Levchenko T.S., and Torchilin V.P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Deliv. Rev. 57 4 (2005) 637-651
50. Herce H.D., and Garcia A.E. Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc. Natl. Acad. Sci. U. S. A. 104 52 (2007) 20805-20810